...
首页> 外文期刊>Prion >Combining autophagy stimulators and cellulose ethers for therapy against prion disease
【24h】

Combining autophagy stimulators and cellulose ethers for therapy against prion disease

机译:结合自噬刺激物和纤维素醚治疗against病毒疾病

获取原文
           

摘要

Prion diseases are fatal transmissible neurodegenerative disorders that affect animals and humans. Prions are proteinaceous infectious particles consisting of a misfolded isoform of the cellular prion protein PrPC, termed PrPSc. PrPSc accumulates in infected neurons due to partial resistance to proteolytic digestion. Using compounds that interfere with the production of PrPSc or enhance its degradation cure prion infection in vitro, but most drugs failed when used to treat prion-infected rodents. In order to synergize the effect of anti-prion drugs, we combined drugs interfering with the generation of PrPSc with compounds inducing PrPSc degradation. Here, we tested autophagy stimulators (rapamycin or AR12) and cellulose ether compounds (TC-5RW or 60SH-50) either as single or combination treatment of mice infected with RML prions. Single drug treatments significantly extended the survival compared to the untreated group. As anticipated, also all the combination therapy groups showed extended survival compared to the untreated group, but no combination treatment showed superior effects to 60SH-50 or TC-5RW treatment alone. Unexpectedly, we later found that combining autophagy stimulator and cellulose ether treatment in cultured neuronal cells mitigated the pro-autophagic activity of AR12 and rapamycin, which can in part explain the in vivo results. Overall, we show that it is critical to exclude antagonizing drug effects when attempting combination therapy. In addition, we identified AR-12 as a pro-autophagic drug that significantly extends survival of prion-infected mice, has no adverse side effects on the animals used in this study, and can be useful in future studies.
机译:on病毒疾病是致命的可传播的神经退行性疾病,会影响动物和人类。 ions病毒是蛋白质感染性颗粒,由细胞a病毒蛋白PrPC的错误折叠同工型组成,称为PrPSc。由于对蛋白水解消化的部分抗性,PrPSc在受感染的神经元中积累。使用会干扰PrPSc产生或增强其降解的化合物在体外可以治愈病毒感染,但是大多数药物在治疗感染pr病毒的啮齿动物时均无效。为了协同抗-病毒药物的作用,我们将干扰PrPSc生成的药物与诱导PrPSc降解的化合物结合使用。在这里,我们测试了自噬刺激物(雷帕霉素或AR12)和纤维素醚化合物(TC-5RW或60SH-50)作为感染RML pr病毒的小鼠的单一治疗或联合治疗。与未治疗组相比,单药治疗显着延长了生存期。如预期的,与未治疗组相比,所有联合治疗组均显示出延长的生存期,但没有联合治疗显示出优于单独的60SH-50或TC-5RW治疗的效果。出乎意料的是,我们后来发现在培养的神经元细胞中结合使用自噬刺激剂和纤维素醚处理可减轻AR12和雷帕霉素的促自噬活性,这可以部分解释体内结果。总体而言,我们表明,在尝试联合治疗时,排除拮抗药物作用至关重要。此外,我们将AR-12确定为一种能促进pha病毒感染小鼠存活的自噬药物,对本研究中使用的动物没有不利的副作用,并且可以在未来的研究中使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号